BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

There is a moment, just as a new technological wave starts to swell, when those creating the platform and those who will be affected by it can come together to shape its future. This moment...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

Patients need to control the use of their data. This calls for new policies on transparency and consent, and means establishing systems governing the ownership, collection and agency of those data. Data privacy is probably...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BC Week In Review | Jan 18, 2019
Company News

Proteus launches digital oral chemo management system

Proteus Digital Health Inc. (Redwood City, Calif.) launched a digital cancer medicine system to help manage oral chemotherapy treatment of stage 3 and 4 colorectal cancer patients. The system, which was developed with the University...
BC Week In Review | Oct 12, 2018
Company News

Otsuka, Proteus to develop additional digital medicine systems

Proteus Digital Health Inc. (Redwood City, Calif.) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) expanded their collaboration to develop and commercialize additional digital medicines over the next five years. Otsuka paid Proteus $88 million in...
BC Week In Review | Nov 17, 2017
Clinical News

FDA approves Abilify tablets with ingestible sensor

FDA approved Abilify MyCite, which combines the antipsychotic Abilify aripiprazole from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) with an ingestible sensor from Proteus Digital Health Inc. (Redwood City, Calif.) in a single tablet to digitally...
BC Extra | Nov 15, 2017
Company News

FDA approves Abilify tablets with ingestible sensor

Late Monday, FDA approved Abilify MyCite, which combines the antipsychotic Abilify aripiprazole from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) with an ingestible sensor from Proteus Digital Health Inc. (Redwood City, Calif.) in a single tablet...
BioCentury | Sep 2, 2017
Strategy

Back to School: Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
BC Week In Review | Aug 18, 2017
Clinical News

FDA approves Abilify for bipolar disorder

H. Lundbeck A/S (CSE:LUN) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA approved an sNDA for once-monthly Abilify Maintena aripiprazole to treat bipolar I disorder. Abilify Maintena is already approved to treat schizophrenia. The...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 166